Expanded Access Policy

 

Cardiff Oncology considers requests from treating physicians for expanded access to onvansertib (PCM-075), our investigational drug, for patients with a serious or immediately life-threatening disease who cannot take part in one of our clinical trials. Onvansertib is an investigational oral PLK1 inhibitor. It has not been approved by the FDA or any other health authority, and its safety and effectiveness have not been established.

Expanded access, sometimes called compassionate use, means giving an investigational drug outside of a clinical trial when no comparable or satisfactory alternative therapy options are available. We review each request individually. Submitting a request does not guarantee that a patient will receive onvansertib, and this page does not promise access to any patient.

Clinical trials come first

Taking part in a clinical trial is the preferred way for patients to receive onvansertib, because trials show whether the drug is safe and effective and help make it available to all patients who may benefit. Patients and physicians can find our current trials at www.ClinicalTrials.gov by searching for onvansertib and looking for trials that may be open to recruitment.

Who can make a request

Only a licensed treating physician can submit a request. We cannot accept requests directly from patients, family members, caregivers, or advocacy groups. Patients who are interested should talk with their own physician about whether expanded access, or a clinical trial, may be an option.

How we evaluate requests

We consider a request only when all of the following general criteria are met:

  • The patient has a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy available.
  • The patient cannot take part in a Cardiff-sponsored clinical trial of onvansertib, for example because the patient does not meet the trial’s eligibility criteria, no trial site is reasonably accessible, or the trial is not enrolling.
  • The available clinical data support a reasonable expectation that the potential benefit to the patient justifies the potential risks.
  • Providing onvansertib will not interfere with the start, conduct, or completion of clinical trials, or otherwise compromise the development of the drug.
  • Enough drug product of appropriate quality is available without affecting the supply needed for our clinical trials.
  • A licensed physician is willing and able to oversee the patient’s treatment, obtain the required regulatory and ethics approvals and informed consent from the patient, and meet safety reporting and drug accountability duties.
  • The request can lawfully be fulfilled under an FDA expanded access pathway or the program that applies in the patient’s country.

 

Meeting these criteria does not oblige Cardiff to grant a request. We may weigh other factors, such as the completeness of the information provided and our ability to support appropriate safety monitoring.

How to submit a request

Physicians should send requests to Cardiff Regulatory Affairs at [email protected]. For an emergency request, please say so in the subject line so we can respond as quickly as possible.

To help us review a request promptly, please include:

  • The licensed physician’s name, institution, and contact details
  • The patient’s age, sex, and country
  • The patient’s diagnosis, histology, and relevant molecular findings, for example RAS mutation status
  • Prior therapies and how the patient responded
  • The patient’s current performance status, organ function, and other medications
  • Why no satisfactory alternative exists and why the patient cannot join a clinical trial
  • The treatment regimen and duration you are requesting

Please limit patient identifiers to the minimum needed. Do not send the patient’s name or other direct identifiers.

What happens after you submit

StepWhat happensTarget timing
1. AcknowledgmentCardiff logs your request and confirms receipt.Within 5 business days of receipt
2. Completeness checkWe ask for any missing information. If we do not receive it within 30 calendar days of our request, we close the request. You may resubmit at any time.Within 10 business days of receipt
3. ReviewA cross-functional Cardiff team reviews the request against the criteria above, including clinical, safety, supply, quality, regulatory, and legal considerations.After we receive a complete request
4. DecisionWe tell you our decision in writing. If we decline, we explain the reason in general terms, and where possible, identify open clinical trials. You may send new information for reconsideration.Within 15 business days of a complete request

Note: The acknowledgment confirms receipt of the request only and does not mean the request has been approved. We will make reasonable efforts to meet the target timings above, but we do not guarantee response times.

If a request is approved

Approval by Cardiff is only the first step. Before we ship any drug:

  • The treating physician must obtain the required regulatory authorization. In the United States, this is usually submission of an individual patient IND (Investigational New Drug Application, Form FDA 3926), and Cardiff provides a Letter of Authorization to support it. Requests from outside the United States follow the rules that apply in that country.
  • Cardiff provides approved requesters with the Investigator’s Brochure and product information.
  • The treating physician must obtain institutional review board (IRB) or ethics committee review where required, and informed consent from the patient or their legally authorized representative.
  • The physician (and the institution, where required) must sign an agreement with Cardiff covering patient oversight, safety reporting, drug accountability, and the return or destruction of unused drug.

The treating physician is responsible for the patient’s care and must report adverse events and product complaints to Cardiff, following the timelines in the agreement. The physician is also responsible for regulatory reporting to the FDA or other applicable health authority when treating a patient under their own individual patient IND.

Cardiff reports safety information to the FDA and other authorities as required under its open INDs.

Cost

Cardiff provides onvansertib for expanded access free of charge. The costs of other medications, medical care, monitoring, and treatment of side effects remain the responsibility of the treating physician, the institution, the patient, or the patient’s payer.

Contact

Cardiff Oncology, Inc.

Email: [email protected]

About this policy

Cardiff may revise this policy at any time, and we will update this page when we do. Posting this policy does not guarantee that any individual patient will receive onvansertib. Cardiff may decline, limit, or stop supply of onvansertib when needed for patient safety, regulatory, quality, supply, or clinical development reasons.

This page is for information only and is not medical advice. Patients should speak with their physician about their treatment options.

Last updated: 20 Nov 2026